Clearside Biomedical (CLSD) Reports In-Line Q3 EPS

Clearside Biomedical (NASDAQ: CLSD) reported Q3 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $260 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Playboy to buy back 16.6M shares from Fortress at $1.05 each